Clinical vignettes for each case identified as high post-test probability considering both NGS somatic testing results and clinical characteristics. Underlined genes were those mutations suspected to be possibly germline (see Methods for details). Supplementary Figure  1 outlines patient pedrigees that were obtained.
Case 3 is a 64 year-old man who was diagnosed with a uT3N3M1, stage IV, gastroesophageal junction (GEJ) cancer after presenting with left cervical lymphadenopathy. An EGD revealed an 8 cm x 1.7 cm mass at the gastric cardia and he was found to have multiple metastatic lymph nodes in the supraclavicular region, mediastinum, carina, and retroperitoneum. Biopsy revealed poorly differentiated adenocarcinoma with signet ring features that was HER2 negative by immunohistochemistry (IHC, 1+ staining) . NGS revealed the following genomic alterations: STK11 F219fs*53, BRCA2 H2417fs*4, TP53 Y163C, ZNF217 amplification. He is an only child with a family history significant for a mother who died of pancreas cancer and a maternal grandmother who died of gastric cancer. He was referred to our Cancer Risk Clinic for further evaluation. BRCA2 mutation was NOT identified in germline DNA. However STK11 was not tested initially (associated with Peutz-Jeghers syndromebreast, colon, pancreas, gastric, etc), and so this was also tested and was found to be NOT germline.
Case 4 is a 61 year-old man with family history of breast cancer (mother, sister) and bladder cancer (brother) who presented to an outside institution with right upper quadrant abdominal pain, hematochezia and weight loss. CT imaging showed multiple hepatic lesions and a colonoscopy revealed a 3 cm mass approximately 20 cm from the anal verge. PET scan showed uptake in the liver, duodenum and colon. Pathologic analysis of the tissue from the colon mass revealed colonic adenocarcinoma which was KRAS wild type, however biopsy of the liver lesion revealed immunohistochemical positivity for CK7, CK20 (focal), CDX2 (weakly) which was more consistent with poorly differentiated cholangiocarcinoma. There was lack of consensus from two Pathology consults with respect to having metastatic colon cancer versus two separate primary cancers (colon and cholangiocarcinoma). Tissue from colon and liver biopsies were sent for NGS sequencing. The liver biopsy specimen was found to have the following genetic alterations: KRAS G12D, BRCA2 K3326*, BRCA2 L2092fs*7, CDKN2A/B loss, MCL1 amplification, MYC amplification, TP53 E51fs*1, GATA3 S382*. Analysis of the colon adenocarcinoma (CRC) specimen identified the following genetic alterations: BRCA2 K3326*, BRCA2 L2092fs*7, APC Y1166*, TP53 R175H. The patient apparently had two separate primary tumors presenting synchronously with different tumor molecular profiles. Importantly, a unifying event was observed with BRCA2, highly indicative of a germline mutation. He was referred to Cancer Risk Clinic for further evaluation. In the process, the patient became aware that his sister was already previously diagnosed with germline BRCA2 mutation for her breast cancer.
Case 5 is a 67 year-old man of Jewish Ashkenazi decent presented with metastatic gastric cancer to the peritoneum. He has a family history significant for cholangiocarcinoma (sister, 50 years-old) and lung cancer in another sister. This patient was not considered for genetic counseling prior to NGS testing. NGS of his tumor tissue revealed the following genetic alterations: KRAS G13D, ERBB4 E1090D, BRCA2 T1345M, BRCA2 S1982fa*22, ARID1A V879fs*12. Germline BRCA2 testing was positive for BRCA2 S1982fa*22 (the other BRCA2 mutation was not tested). This patient had 2 daughters. Both daughters were screened and one of the two was confirmed to be a germline BRCA2 carrier. She met with a genetic counselor who presented the options of annual screening mammography and MRI or prophylactic bilateral mastectomy and salpingo-oophorectomy. At present, her preference is to undergo prophylactic surgery.
Case 6 is a 81 year-old man with metastatic gastric adenocarcinoma. He has family history of breast and ovarian cancer in his mother, and lung cancer in his brother. NGS of his tumor tissue revealed the following genetic alterations: PIK3CA H1047R, PTCH1 R1308fs*64, MLH1 N168fs*34, MSH6 V592fs*6. Unfortunately, he died prior to being able to acquire germline testing.
Case 7 is a 77 year-old man with stage IIA (T3N0) gastric adenocarcinoma who is currently undergoing perioperative FOLFOX chemotherapy with plan to proceed to surgical resection if appropriate after completion of neoadjuvant therapy. His family history is notable for as sister with colorectal cancer. His tumor tissue was analyzed by NGS revealing the following genomic alterations: ERBB3 V104M, NF1 R816*, PIK3CA H1047Y, ARID1A A1304fs*177, KDR R275*, MLH1 S456*, AXL T343M, CREBBP R1664C, CTCF N105fs*14. This patient died prior to acquiring germline testing.
Case 8 is a 62 year-old man with metastatic rectal cancer and no significant family history of malignancy. NGS of his tumor tissue revealed the following genetic alterations: KRAS G12V, BRCA2 S3366fs*4, APC E991* E1397*. He accepted genetic counseling and germline testing. Germline BRCA2 testing confirmed the presence of a BRCA2 S3366fs*4 mutation. He was seen by a genetic counselor, along with his two daughters, who will continue to work with the counselors to plan an appropriate screening program based on their estimated risk.
Case 9 is a 76 year-old woman with TXNXM1, HER2 negative, gastric adenocarcinoma. She presented initially with a right neck mass which was found to be poorly differentiated carcinoma and ultimately determined to represent a metastatic focus of gastric adenocarcinoma. The extent of her metastatic disease included bilateral ovarian involvement, bone metastasis and mesenteric and retroperitoneal lymph node metastasis. There was vague history of several family members having gastric cancer. NGSbased assay identified a sole CDH1 R74* (e-cadherin) genomic alteration. Germline testing did NOT reveal mutation in CDH1.
Case 10 is a 26 year-old man with metastatic cholangiocarcinoma (gallbladder) diagnosed after initially presenting with a feeling of "fluid moving around" in his abdomen while he was jogging. His cancer had metastasized to the liver and peritoneum causing malignant ascites. There was a possible history of "gallbladder issues" in the family but, otherwise, no known history of cancer. NGS of his tumor tissue revealed an ATMR1898* mutation and ARID1A S254fs*104. He accepted genetic counseling and germline testing. Germline testing did NOT reveal an ATM mutation. Patient died 3 months after his diagnosis.
Case 11 is a 76 year-old woman with metastatic cholangiocarcinoma. She has a personal history of breast cancer 13 years ago, status post lumpectomy, radiation and chemotherapy. Routine follow-up imaging revealed gallbladder thickening and PET scan revealed a hypermetabolic mass in the right lobe of the liver and an enlarged, hypermetabolic, peri-pancreatic node. With no other overt sites of metastatic disease she underwent exploratory laparotomy. Intraoperatively she was noted to have multiple hepatic lesions and the enlarged peri-pancreatic node, with apparent origin from the gallbladder. A cholecystectomy was performed and pathology was consistent with cholangiocarcinoma. She has a family history significant for a paternal cousin who was diagnosed with ovarian cancer in her early 40s, and a great aunt with colorectal cancer at age 70. NGS of her tumor tissue revealed STK11 loss and CDKN2A/B loss. She died prior to being contacted for counseling or germline testing.
Case 12 is a 31 year-old male with metastatic rectal cancer, with metastatic disease involving his lungs. He had a personal history of antiphospholipid antibody syndrome and a family history of a maternal grandmother with colorectal cancer at age 57, two maternal great aunts with lymphoma, and one paternal uncle with non-melanoma skin cancer. NGS of his tumor tissue revealed mutations in APCK1165* and a KRAS G12D which was sub-clonal. He accepted genetic counseling but declined germline testing.
Case 13 is a 38 year-old man with metastatic gastroesophageal cancer. He had no known family history of cancer. NGS of his tumor revealed STK11 loss . Patient died prior to being contacted for counseling or germline testing.
Case 14 is a 43 year-old woman with metastatic gastric adenocarcinoma, diffusely involving her peritoneal cavity. She has a family history notable for a sister with ovarian cancer at age 26 years. NGS of her tumor tissue revealed CDK1E518fs*4 and CDH1 splice 1320+1G>T. These mutations were NOT found to be germline on confirmatory testing.
Case 15 is a 47 year-old woman with metastatic gastric adenocarcinoma. She has a family history notable for a father with lung and colorectal cancer, diagnosed at age 72. It is not clear whether her father had two separate primary malignancies or pulmonary metastasis from colorectal cancer. NGS of her tumor revealed a CDH1F602fs*11 mutation. She was lost to follow up prior to receiving genetic counseling or germline testing.
Case 16 is s 73 year-old woman with metastatic adenocarcinoma-likely gastric-involving the GE junction, liver, peritoneum and soft tissue of the abdomen. She has a family history notable for a paternal grandfather with bladder cancer at age 70, and a mother who had a unilateral mastectomy at age 54 for unclear reasons (but presumed, by family, to be due to breast cancer). NGS of her tumor tissue revealed a BRCA K3326* mutation. She was seen by a genetic counselor who informed her that, due to the fact that this particular BRCA2 mutation is predicted to function in a similar manner as the normal BRCA2 gene product, this mutation is classified by Myriad Genetic Labs as a polymorphism. Therefore germline testing was not recommended.
Case 17 is a 66 year-old woman with gastric adenocarcinoma as well as a history of colorectal cancer 18 years prior AND nine years prior -for which she underwent surgical resection and chemotherapy. NGS of her gastric tumor biopsy revealed an MSH T44fs*20 mutation. She declined genetic counseling or germline testing, and it was discovered that she had previously declined genetic couseling prior to NGS. This case emphasizes the importance of establishing patient wishes in terms of NGS result disclosure prior to obtaining tumor NGS, as in Table 2 .
Case 18 is a 77 year-old man with duodenal adenocarcinoma as well as hepatocellular carcinoma. He has no known family history of cancer. NGS was obtained for the duodenal adenocarcinoma, but not the HCC. It revealed an MSH6 K1358fs*2 mutation. He was lost to follow up prior to receiving genetic counseling or germline testing.
Case 19 is a 37 year-old man with gastric adenocarcinoma. He has a family history of a maternal grandmother with lung, breast and colon cancer and a paternal grandmother with lymphoma. NGS of his tumor tissue revealed an APC S1194* mutation. He declined genetic counseling or germline testing.
Case 20 is a 70 year-old man with gastric cancer. He also has a personal history of GEJ cancer diagnosed at age 56, 14 years prior. His family history is notable for a mother with breast cancer, father with prostate cancer, paternal grandfather with gastric cancer and sister with breast cancer. NGS of his tumor tissue revealed a truncating mutation in CDH1 (CDH1 W20fs*9). He was seen by a genetic counselor and elected to have his blood drawn for germline testing however, the results had not returned prior to this publication of this report.
Case 21 is a 48 year-old woman with metastatic gastric adenocarcinoma. She has a family history significant for a father with brain cancer at age 58. NGS of her tumor revealed a CDH1 splice site 531+1G>T mutation. She was lost to follow up prior to undergoing genetic counseling or germline testing.
The positive control was a 61 year-old man with a known history of Gorlin Syndrome, diagnosed based on his clinical history of multiple basal cell skin cancers. This syndrome is knowed to be associated with a germline mutation in the PTCH1 gene. He has two children, a son and daughter, who also have this clinical syndrome. He developed gastric adenocarcinoma and his tumor NGS was done as a positive control to determine the underlying germline mutation. This revealed a previously undetermined PTCH1 G511fs*31 mutation.
